According to recent guidelines, endocrine therapy should be the treatment of choice for most patients with advanced or metastatic ER+, PR+/HER2 (−) breast cancer unless there is evidence of rapidly progressive visceral disease with organ dysfunction or imminent organ failure [27,28]. Here, ESR1 is linked to breast carcinoma.